News Orchard’s MLD gene therapy becomes costliest US medicine Orchard Therapeutics has revealed its US pricing plans for Lenmeldy, its gene therapy for metachromatic leukodystrophy (MLD), placing a $4.25 million price tag on the one-
News Orchard's gene therapy for MLD finally gets US approval The FDA has cleared its first gene therapy for kids with metachromatic leukodystrophy (MLD), a rare genetic disorder of the brain and nervous centre.
News Alarm as Trump peddles unproven causes of autism Medical groups have reacted with dismay after Trump linked childhood vaccinations and use of acetaminophen to autism.
Sales & Marketing FH25: Individual centric investing with Steve Seuntjens In a new FH25 podcast episode, Deep Dive editor Eloise McLennan speaks with Steve Seuntjens, Partner at PHS Capital.